An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
Stopped Study was terminated due to the inability to enroll a sufficient number of the required subject population
Conditions
- Inflammatory Bowel Diseases
Interventions
Sponsor
Janssen Scientific Affairs, LLC